Finland-based Rappta Therapeutics Oy has appointed Sunjeet Sawhney as chief executive to manage development of its cancer drugs that reactivate PP2A, an enzyme that regulates protein de-phosphorylation. He was most recently global head of oncology at Ipsen SA. Mr Sawhney holds an MSc degree in immunology from the University of London, UK, where he will be based. Rappta’s co-founder and founding CEO Mikko Mannerkoski has become chief financial officer.
Rappta Therapeutics announced the appointment on 15 September 2021.
Copyright 2021 Evernow Publishing Ltd.